SYRE: Spyre Therapeutics, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 17 sales totaling $6.28M in the last 180 days.
Insider sales
| Trade date | Insider | Role | Value | 10b5-1 plan |
|---|---|---|---|---|
| 2026-10-01 | King-Jones Heidy | Officer | $36K | yes |
| 2026-10-01 | King-Jones Heidy | Officer | $1.50M | yes |
| 2026-10-01 | King-Jones Heidy | Officer | $660K | yes |
| 2026-10-01 | King-Jones Heidy | Officer | $195K | yes |
| 2026-10-01 | King-Jones Heidy | Officer | $243K | yes |
| 2026-10-01 | Turtle Cameron | CEO | $53K | yes |
| 2026-10-01 | Turtle Cameron | CEO | $242K | yes |
| 2026-10-01 | Turtle Cameron | CEO | $241K | yes |
| 2026-10-01 | Turtle Cameron | CEO | $368K | yes |
| 2026-10-01 | Turtle Cameron | CEO | $466K | yes |
| 2026-10-01 | Turtle Cameron | CEO | $9K | yes |
| 2026-10-01 | Burrows Scott L | CFO | $53K | yes |
| 2026-10-01 | Burrows Scott L | CFO | $135K | yes |
| 2026-10-01 | Burrows Scott L | CFO | $193K | yes |
| 2026-10-01 | Burrows Scott L | CFO | $285K | yes |
| 2026-10-01 | Burrows Scott L | CFO | $21K | yes |
| 2026-09-30 | Burrows Scott L | CFO | $1.57M | yes |
Activist and 5% holders
| Filed | What | Holder | Stake | Change | Filing |
|---|---|---|---|---|---|
| 2026-10-09 | 13D amendment | Fairmount Funds Management LLC | 9.99% | SEC | |
| 2026-10-01 | New 13G stake | Paradigm BioCapital Advisors LP | 5.10% | SEC |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.